NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Absolutely! No other companies have the treatments that can trigger the same magnitude of anti-tumor response as NWBO's DCVax-L. This company on the news would not pose any competition to NWBO either.

IMO, Merck could be among the ones that have been suppressing the news coverage of NWBO until the time is right for Merck. Which company could force AI to take down Dr. Liau's webinar video twice? Only the most relevant one.

As the Company previously reported, proteomic studies have demonstrated that a single tumor lysate sample contained tens of thousands of different peptides and, out of this pool, the dendritic cells selected, processed and presented over 600 different peptides (tumor targets) to T cells. T cell studies (TCR sequencing and T cell clonal expansion assays) analyzing the breadth and strength of T cell response following DCVax-L treatment have found extensive responses, including clonal expansion of up to 800 T cell clones at month 4 and up to 1200 T cell clones at month 8 in the samples studied. Each T cell clone focuses on a particular and distinct target. In individuals not being treated with the vaccine, only 2 – 20 new T cells clones are seen between month 4 and month 8.

The results of these proteomic, T cell and other studies provide support for what the Company believes to be the mechanism of action of DCVax-L: i.e., mobilizing a broad spectrum and strong de novo T cell response that addresses the extensive heterogeneity of GBM and overcomes the immunosuppressive microenvironment around the tumor.

https://classic.clinicaltrials.gov/ct2/show/NCT02301611?cond=NCT02301611&draw=2&rank=1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/pdf/10434_2021_Article_9709.pdf